TNON

Tenon Medical, Inc.

9 filings tracked

healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 22

Nasdaq issued a notice of non-compliance regarding minimum stockholders' equity.

regulatory action

80%

bearishMay 22

Requirement to regain equity compliance likely necessitates a capital raise.

dilution risk

70%

bearishMay 22

Nasdaq issued a notice of non-compliance regarding minimum stockholders' equity.

regulatory action

80%

bearishMay 22

Requirement to regain equity compliance likely necessitates a capital raise.

dilution risk

70%

bearishMay 22

Nasdaq issued a notice of non-compliance regarding minimum stockholders' equity.

regulatory action

80%

bearishMay 22

Requirement to regain equity compliance likely necessitates a capital raise.

dilution risk

70%

bearishMay 22

Nasdaq issued a notice of non-compliance regarding minimum stockholders' equity.

regulatory action

80%

bearishMay 22

Requirement to regain equity compliance likely necessitates a capital raise.

dilution risk

70%

bearishMay 22

Nasdaq issued a notice of non-compliance regarding minimum stockholders' equity.

regulatory action

80%

bearishMay 22

Requirement to regain equity compliance likely necessitates a capital raise.

dilution risk

70%

bearishMay 22

Nasdaq issued a notice of non-compliance regarding minimum stockholders' equity.

regulatory action

80%

bearishMay 22

Requirement to regain equity compliance likely necessitates a capital raise.

dilution risk

70%

bearishMay 15

Net loss of $3.48M remains high relative to revenue.

earnings miss

70%

bullishMay 15

Gross margin increased significantly from 44% to 69%.

margin expansion

90%

neutralMay 15

Raised $4.3M via convertible notes to extend liquidity runway.

capital raise

60%

bearishMay 15

Received Nasdaq notice regarding bid price deficiency.

regulatory action

80%

bearishMay 15

Net loss of $3.48M remains high relative to revenue.

earnings miss

70%

bullishMay 15

Gross margin increased significantly from 44% to 69%.

margin expansion

90%

neutralMay 15

Raised $4.3M via convertible notes to extend liquidity runway.

capital raise

60%

bearishMay 15

Received Nasdaq notice regarding bid price deficiency.

regulatory action

80%

bullishMar 27

Gross margins improved from 52% to 60% in fiscal 2025.

margin expansion

70%

bearishMar 27

Issuance of $5.2M in senior convertible notes with high OID and potential for 33M shares dilution.

dilution risk

90%

bullishMar 27

Acquisition of SImmetry+ platform expands product offering and market reach.

acquisition

60%

bearishMar 27

Nasdaq notification of non-compliance with minimum bid price rule.

regulatory action

80%

Filing History

8-KMay 22, 2026

Tenon Medical is currently navigating a critical regulatory window after failing to meet Nasdaq's minimum stockholders' equity requirement of $2.5 million. While the company reported equity of $1.895 million, it now has until July 6, 2026, to submit a compliance plan. The outcome hinges on whether management can secure a non-dilutive path to compliance or if they will be forced into a fire-sale financing round. Investors are now weighing the possibility of a quick resolution against the risk of a downward spiral toward delisting and severe equity dilution.

10-QMay 15, 2026

The Q1 2026 filing reveals a company at a crossroads between genuine commercial scaling and a looming liquidity crisis. While the revenue growth and margin expansion are objectively impressive, they are currently overshadowed by a net loss that is 252% of total sales. The successful acquisition of the SImmetry+ system has provided the growth engine the company desperately needed, but the cost of maintaining that engine is currently higher than the revenue it generates. Investors are now weighing the potential of a high-growth medical device portfolio against the immediate risks of shareholder dilution and potential delisting. The recent issuance of convertible notes provides a temporary reprieve, but the long-term viability of the company depends on whether the current revenue trajectory can reach a breakeven point before the cash reserves are exhausted. The tension between the accelerating top line and the deteriorating balance sheet defines the current investment profile for Tenon.

10-KMar 27, 2026

The 10-K reveals a company at a crossroads: possessing a clinically validated product suite in a massive untapped market, yet operating on the brink of financial collapse. The acquisition of SImmetry+ and the positive data from the Mainsail study provide a credible product narrative, but these are currently overshadowed by a balance sheet that cannot support the current burn rate. The tension between the high-growth potential of the SI joint market and the immediate risk of delisting or bankruptcy creates a high-risk, high-reward profile. Investors are essentially betting on whether Tenon can accelerate its commercial inflection point before its cash reserves and Nasdaq compliance window expire. The ability to secure non-dilutive funding or a strategic partnership will be the deciding factor in whether the company survives to capture the market share it envisions.